chufangao/CTO huggingface dataset:
Clinical trial NCT04347486: Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children
Official title: Pharmacokinetic-pharmacodynamic Analysis of Conventional Reversal of Rocuronium-induced Neuromuscular Blockade by Sugammadex in Children
Sponsor: Seoul National University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-29
Primary completion date: 2021-12-07
Completion date: 2021-12-07
Plan to share individual participant data: NO
Clinical trial NCT04551898: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 181.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-02
Primary completion date: 2021-05-25
Completion date: 2021-05-25
Baseline population: Intent to treat (ITT) analysis set includes all randomized participants.
Plan to share individual participant data: YES
Clinical trial NCT04348513: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
Official title: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)
Acronym: Thy-Support
Sponsor: Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to specific inclusion criteria no more subjects could be enrolled.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-29
Primary completion date: 2021-04-19
Completion date: 2021-04-19
Plan to share individual participant data: NO
Clinical trial NCT03386214: Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Official title: Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor stopped development of pevonedistat
Enrollment: 8.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-04-23
Primary completion date: 2021-09-12
Completion date: 2021-10-04
Plan to share individual participant data: NO
Clinical trial NCT03395314: Ketamine in Borderline Personality Disorder
Official title: A Randomized Active Placebo Controlled Trial of Ketamine in Borderline Personality Disorder
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: assessment of project in wake of covid-19 related interruptions
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-15
Primary completion date: 2022-05-06
Completion date: 2022-05-06
Plan to share individual participant data: NO
Clinical trial NCT02629419: CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Official title: A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies
Acronym: CAMB
Sponsor: Matinas BioPharma Nanotechnologies, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-27
Primary completion date: 2021-11-09
Completion date: 2022-08-06
Limitations and caveats: Did not reach target number of participants (small sample size). All participants were female and Caucasian.
Clinical trial NCT03176784: UW Quitting Using Intensive Treatment Study (QUITS)
Official title: UW Quitting Using Intensive Treatment Study
Acronym: QUITS
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1251.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-11-11
Primary completion date: 2020-07-09
Completion date: 2020-07-09
Plan to share individual participant data: YES
IPD sharing description: De-identified data set will be posted by UW-CTRI in accord with NHLBI policies
IPD time frame: 12 months after publication of the primary outcome paper.
IPD access criteria: Prior written data request to the PI.
Clinical trial NCT03847922: Nitrous Oxide for Analgesia During Office Urethral Bulking
Official title: Nitrous Oxide for Analgesia During Office Urethral Bulking: a Randomized, Controlled Trial
Sponsor: Baylor Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to staffing changes in the hospital, we will be unable to complete this study for the requested 84 subjects. As such, we have decided to close this study.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-15
Primary completion date: 2020-07-23
Completion date: 2020-07-23
Plan to share individual participant data: NO
IPD sharing description: No IPD will be shared with other researchers. Once all data is collected for a specific patient, it will be deidentified and entered in a spread sheet to be used for this study only.
Clinical trial NCT03723915: Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Official title: A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-14
Primary completion date: 2019-12-19
Completion date: 2021-04-24
Baseline population: Only patients who were treated on study were included. 2 patients were screen fails, and 2 patients became ineligible for treatment and did not receive study drug--these patients were not included here.
Limitations and caveats: The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.
Clinical trial NCT03094832: Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
Official title: A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome
Acronym: MOSAIC
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Early termination due to business reasons
Enrollment: 50.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-05-16
Primary completion date: 2022-04-11
Completion date: 2022-04-11
Limitations and caveats: Early termination due to business reasons
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03644706: Study Evaluating Subjects With Distal Renal Tubular Acidosis
Official title: A Phase 3 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Withdrawal Study Evaluating ADV7103 In Pediatric and Adult Subjects With Distal Renal Tubular Acidosis (dRTA)
Sponsor: Advicenne Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Research operation issues
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-20
Primary completion date: 2023-12-20
Completion date: 2023-12-20
Plan to share individual participant data: NO
Clinical trial NCT03419897: Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
Official title: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 249.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-09
Primary completion date: 2021-06-30
Completion date: 2022-07-06
Plan to share individual participant data: YES
Clinical trial NCT02995733: Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief
Official title: Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations
Acronym: PREPARE
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1220.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-27
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Baseline population: 19 participants were dropped from analysis due to the site closure. They were not followed and not included in any analyses.
Plan to share individual participant data: NO
Clinical trial NCT03346681: N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome
Official title: N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome
Acronym: NARDS
Sponsor: Prisma Health-Midlands (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: no patients enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-01
Primary completion date: 2021-01-30
Completion date: 2021-01-30
Plan to share individual participant data: NO
Clinical trial NCT04060407: CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Official title: Phase Ib/II Study Combining CD24Fc With Checkpoint Inhibitors for Patients With Metastatic Melanoma
Acronym: CINDI
Sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Business Reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-15
Primary completion date: 2022-12-30
Completion date: 2023-12-30
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04608266: CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
Official title: A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)
Acronym: CAMOVID
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Scientific committee decision due SARS-CoV2 pandemic evolution with a decrease in inclusions and widespread distribution of vaccines
Enrollment: 70.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-03
Primary completion date: 2021-09-27
Completion date: 2021-12-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03682367: Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
Official title: Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery: A Randomized Controlled Trial
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Poor Recruitment
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-01
Primary completion date: 2020-04-01
Completion date: 2020-04-06
Limitations and caveats: Early study termination was decided after several technical issues regarding study logistics and patient non-compliance lead to unreliable and uninterpretable data.
Plan to share individual participant data: NO
Clinical trial NCT05299580: Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)
Official title: Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)
Sponsor: Fondazione Melanoma Onlus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: lack of enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-18
Primary completion date: 2023-03-30
Completion date: 2023-03-30
Clinical trial NCT02720185: Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Official title: Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor (nEGFR)
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated early due to COVID-19 related slow enrollment and funding
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-03
Primary completion date: 2020-07-02
Completion date: 2022-02-08
Limitations and caveats: Statistical analyses were not completed for this study as it was not powered for meaningful results. Study was terminated early due to pandemic related enrollment issues, participants moved on to other therapies compromising intervention-relevant long term AE follow up.
Clinical trial NCT03431480: Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart Surgery
Official title: Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation
Sponsor: Murdoch Childrens Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-16
Primary completion date: 2021-11-01
Completion date: 2022-06-30
Plan to share individual participant data: UNDECIDED
IPD sharing description: IPD may be available following study publication and discussion between CIs and other researchers regarding future multicentre studies.
Clinical trial NCT02382406: Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Official title: A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was completed. It was fully accrued.
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-06-04
Primary completion date: 2022-04-14
Completion date: 2022-04-14
Baseline population: No subjects had been enrolled to Phase I, Cohort 2.
Plan to share individual participant data: NO
Clinical trial NCT05080842: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
Sponsor: Accutar Biotechnology Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Voluntarily terminate the study since the sponsor's development strategy was adjusted.
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-12
Primary completion date: 2024-04-04
Completion date: 2024-04-04
Plan to share individual participant data: NO
Clinical trial NCT04296396: Opioid Prescription After Cesarean Trial
Official title: Prescription After Cesarean Trial
Acronym: PACT
Sponsor: The George Washington University Biostatistics Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 5521.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-21
Primary completion date: 2022-04-07
Completion date: 2022-07-08
Baseline population: Baseline data were collected once for the one participant who re-enrolled
Plan to share individual participant data: YES
IPD sharing description: The dataset will be shared per NIH policy after the completion and publication of the main analyses. Data will be available through the NICHD Data and Specimen Hub.
Clinical trial NCT01825369: Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow
Official title: Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow
Acronym: L-carn
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Changes to cardiac surgery program
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-12-31
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Clinical trial NCT04532801: Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance
Official title: Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Interim analysis of data collected under other clinical trials demonstrated planned enrollment was insufficiently powered.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-01
Primary completion date: 2024-08-31
Completion date: 2024-12-21
Plan to share individual participant data: NO
Clinical trial NCT04966338: Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
Official title: A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active-controlled Clinical Trial to Evaluate Equivalency of the Efficacy and Safety of Ocrelizumab (CinnaGen, Iran) in Comparison to Reference Product, Ocrevus® (Roche, Switzerland) in Patients With Relapsing Multiple Sclerosis
Sponsor: Cinnagen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 170.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-19
Primary completion date: 2020-11-09
Completion date: 2021-10-01
Plan to share individual participant data: NO
Clinical trial NCT04508140: Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Official title: Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer
Sponsor: Highlight Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment rate
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-17
Primary completion date: 2022-12-02
Completion date: 2022-12-02
Plan to share individual participant data: NO
Clinical trial NCT04115956: A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Official title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
Sponsor: Oncopeptides AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-06
Primary completion date: 2022-01-05
Completion date: 2022-01-05
Clinical trial NCT04915404: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
Official title: A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy
Sponsor: WPD Pharmaceuticals Sp. z o.o. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-07
Primary completion date: 2023-12-30
Completion date: 2023-12-30
Plan to share individual participant data: NO
Clinical trial NCT03244982: Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein
Official title: Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg
Sponsor: Kresge Eye Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: Additional data may be required once preliminary data is analyzed.
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-05
Primary completion date: 2019-07-17
Completion date: 2020-12-01
Plan to share individual participant data: NO
Clinical trial NCT04074317: Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
Official title: A Phase 2, Single-Dose, Randomized, Open-Label, Active-Controlled, Crossover, Pharmacodynamic, and Pharmacokinetic Comparative Study of a Novel Pramlintide-Insulin Co-Formulation in Adults With Type 1 Diabetes Mellitus
Sponsor: Xeris Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-08-22
Primary completion date: 2020-04-02
Completion date: 2020-04-02
Baseline population: Baseline characteristics by enrollment arm.
Plan to share individual participant data: NO
Clinical trial NCT04613102: The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial
Official title: The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial
Sponsor: The Hospital for Sick Children (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: The study protocol should to be updated (major updates), following the second Health Canada review /requests. The study has been withdrawn form the REB review and will not be performed at SickKids.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2022-09-01
Completion date: 2022-12-30
Plan to share individual participant data: NO
Clinical trial NCT03247413: Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation
Official title: Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study has been halted prematurely
Enrollment: 63.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-01
Primary completion date: 2022-10-14
Completion date: 2022-10-14
Clinical trial NCT03730948: DC Vaccine in Colorectal Cancer
Official title: Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal Cancer
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-12
Primary completion date: 2022-02-22
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT05137795: Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Official title: Inhaled ZYESAMI (Aviptadil Acetate) for the Treatment of Severe COVID-19 (AVICOVID-3)
Acronym: AVICOVID-3
Sponsor: APR Applied Pharma Research s.a. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-15
Primary completion date: 2022-06-15
Completion date: 2022-08-15
Plan to share individual participant data: UNDECIDED